Nordic Nanovector

Nordic Nanovector is a Norwegian biotech company developing antibody radionuclide conjugates. The company's lead product is Betalutin for the treatment of B-cell non-Hodgkin lymphoma. The [...] will irradiate malignant metastasized tumours with minor damage to healthy normal tissue. The company is listed at Oslo STOCK Exchange.

History

Nordic Nanovector was founded by Roy Larsen, Øyvind Bruland and Jostein Dahle. Larsen and Bruland also founded Algeta, which was acquired by Bayer in 2013.

Betalutin

Betalutin comprises a tumour seeking mure monoclonal antibody against CD37 conjugated to Lutetium-177, a low intensity radionuclide. Betalutin targets the cell-surface CD37 antigen, which is found on more than 80% of non-Hodgkin lymphomas. The antibody is a proprietary antibody developed by the Norwegian Radium Hospital in the 1980s. The [...] causes targeted cell death in the tumour through irreversible DNA breaks, inhibition of cell division and apoptosis. Betalutin is administered as a single injection, and the half-life of Lutetium-177 is 6.7 days.

Betalutin is currently in a Phase I/II trial in difficult to treat non-Hodgin lymphoma patient population.